Skip to main content
Clinical Trials/NCT06347835
NCT06347835
Not yet recruiting
Not Applicable

Biomarker Identification and Nutritional Intervention of Primary Sarcopenia Based on Gut-muscle Axis

Peking Union Medical College Hospital1 site in 1 country120 target enrollmentApril 2024
ConditionsSarcopenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcopenia
Sponsor
Peking Union Medical College Hospital
Enrollment
120
Locations
1
Primary Endpoint
Change from Baseline of Appendicular skeletal muscle mass index at 12 weeks
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The loss of skeletal muscle mass and function usually occurs with aging, known as primary sarcopenia. Sarcopenia has a prevalence of 11.6% among the elderly population in China and is closely associated with increased risks of falls, disability, and mortality. Currently, there is a lack of definition criteria for sarcopenia based on biomarkers. The Gut-Muscle Axis hypothesis suggests a complex interplay between gut microbiota and skeletal muscle. Nutritional intervention targeting the gut microbiota potentially plays a significant role in muscle regeneration. Therefore, this study aims to explore the effects of symbiotic and whey protein on muscle, gut microbiota, and clinical outcomes among sarcopenia patients, to provide a reference for further diagnosis and treatment of sarcopenia.

Detailed Description

This study will last 12 weeks. For the duration of the study, an anticipated total of 120 participants will be randomly assigned to three groups. During the study visits, questionnaires, blood and stool collection, and functional testing will occur. Intention-to-treat analysis (ITT) and per-protocol analysis (PP) will be conducted in statistical analysis.

Registry
clinicaltrials.gov
Start Date
April 2024
End Date
January 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yu Kang, MD

Professor

Peking Union Medical College Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 65 and older
  • Can cooperate with the measurement and questionnaire survey
  • Meets Asian Working Group for Sarcopenia (AWGS) 2019 diagnostic criteria for sarcopenia
  • Obtain informed consent to participate in this study

Exclusion Criteria

  • Severe complications
  • Suffers from neuromuscular related diseases
  • Have taken antibiotics, probiotics and other medications that may affect the gut microbiota in the last 6 weeks
  • Implants of electronic devices or metal objects in the body

Outcomes

Primary Outcomes

Change from Baseline of Appendicular skeletal muscle mass index at 12 weeks

Time Frame: 12 weeks

Defined as muscle mass (Unit: kg/m2)

Change from Baseline of grip strength at 12 weeks

Time Frame: 12 weeks

Defined as muscle strength (Unit: kg)

Secondary Outcomes

  • Change from Baseline of inflammation status at 12 weeks(12 weeks)
  • Change from Baseline of gut microbiota composition at 12 weeks(12 weeks)
  • Change from Baseline of Short Physical Performance Battery score at 12 weeks(12 weeks)
  • Change from Baseline of gait speed at 12 weeks(12 weeks)
  • Change from Baseline of microbiota-derived metabolites at 12 weeks(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials